Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

James Cooper to Humans

This is a "connection" page, showing publications James Cooper has written about Humans.

 
Connection Strength
  
 
 
0.218
  
  1. Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, Grafals M, Pomfret E, Nickerson P, Cooper JE. Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. Am J Transplant. 2021 01; 21(1):322-328.
    View in: PubMed
    Score: 0.020
  2. Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 04; 104(4):881-887.
    View in: PubMed
    Score: 0.019
  3. Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. Clin J Am Soc Nephrol. 2020 03 06; 15(3):430-438.
    View in: PubMed
    Score: 0.019
  4. Cooper JE. Desensitization in Kidney Transplant: A Risky (but Necessary?) Endeavor for Those With Limited Options. Transplantation. 2019 12; 103(12):2460-2461.
    View in: PubMed
    Score: 0.019
  5. Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
    View in: PubMed
    Score: 0.016
  6. Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients. Transplant Rev (Orlando). 2017 01; 31(1):47-54.
    View in: PubMed
    Score: 0.015
  7. Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation. 2014 Jun 27; 97(12):1253-9.
    View in: PubMed
    Score: 0.013
  8. Alfonso J, Gralla J, Klem P, Chan L, Wiseman AC, Cooper JE. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts. Clin Transpl. 2014; 161-70.
    View in: PubMed
    Score: 0.013
  9. Cooper JE, Wiseman AC. Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):698-703.
    View in: PubMed
    Score: 0.012
  10. Cooper JE, Gralla J, Adebiyi O, Wiseman AC, Chan L. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Clin Transpl. 2013; 407-12.
    View in: PubMed
    Score: 0.012
  11. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011 May 27; 91(10):1103-9.
    View in: PubMed
    Score: 0.010
  12. Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011; 359-64.
    View in: PubMed
    Score: 0.010
  13. Cooper JE, Huskey J, Chan L, Wiseman AC. Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation. 2010 Aug 15; 90(3):331-2.
    View in: PubMed
    Score: 0.010
  14. Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases. Clin Transpl. 2010; 415-20.
    View in: PubMed
    Score: 0.010
  15. Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Clin Transpl. 2009; 455-9.
    View in: PubMed
    Score: 0.009
  16. Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant. 2018 02; 16(1):23-30.
    View in: PubMed
    Score: 0.004
  17. Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015 Jun; 26(6):1248-60.
    View in: PubMed
    Score: 0.003
  18. Gralla J, Le CN, Cooper JE, Wiseman AC. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant. 2014 Mar; 28(3):292-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)